Novo Nordisk A/S (BSP:N1VO34) Net Issuance of Debt : R$-1,061 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Novo Nordisk A/S Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Novo Nordisk A/S's net issuance of debt for the three months ended in Dec. 2023 was R$-254 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2023 was R$-1,061 Mil.

Novo Nordisk A/S Net Issuance of Debt Historical Data

The historical data trend for Novo Nordisk A/S's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Net Issuance of Debt Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

Get a 7-Day Free Trial

-452.40

3,980.89

13,293.87

-1,798.53

-1,051.68

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Debt	Get a 7-Day Free Trial															-96.35	-358.12	-263.45	-184.47	-254.50

Novo Nordisk A/S Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-1,061 Mil.

Novo Nordisk A/S Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (BSP:N1VO34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (BSP:N1VO34) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S (BSP:N1VO34) Headlines

No Headlines